Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin

Institute for Regenerative Cures, University of California Davis Health System, 2921 Stockton Blvd Room #1300, Sacramento, CA 95817, USA.
Molecular and Cellular Neuroscience (Impact Factor: 3.84). 12/2011; 49(3):271-81. DOI: 10.1016/j.mcn.2011.12.001
Source: PubMed


Huntington's disease (HD) is a fatal, autosomal dominant neurodegenerative disorder caused by an expanded trinucleotide (CAG) repeat in exon 1 of the huntingtin gene (Htt). This expansion creates a toxic polyglutamine tract in the huntingtin protein (HTT). Currently, there is no treatment for either the progression or prevention of the disease. RNA interference (RNAi) technology has shown promise in transgenic mouse models of HD by reducing expression of mutant HTT and slowing disease progression. The advancement of RNAi therapies to human clinical trials is hampered by problems delivering RNAi to affected neurons in a robust and sustainable manner. Mesenchymal stem cells (MSC) have demonstrated a strong safety profile in both completed and numerous ongoing clinical trials. MSC exhibit a number of innate therapeutic effects, such as immune system modulation, homing to injury, and cytokine release into damaged microenvironments. The ability of MSC to transfer larger molecules and even organelles suggested their potential usefulness as delivery vehicles for therapeutic RNA inhibition. In a series of model systems we have found evidence that MSC can transfer RNAi targeting both reporter genes and mutant huntingtin in neural cell lines. MSC expressing shRNA antisense to GFP were found to decrease expression of GFP in SH-SY5Y cells after co-culture when assayed by flow cytometry. Additionally MSC expressing shRNA antisense to HTT were able to decrease levels of mutant HTT expressed in both U87 and SH-SY5Y target cells when assayed by Western blot and densitometry. These results are encouraging for expanding the therapeutic abilities of both RNAi and MSC for future treatments of Huntington's disease.

Download full-text


Available from: Jan A Nolta, Jul 03, 2015
  • Source
    • "Several studies have evidenced successful loading of siRNAs and miRNAs into EVs with constructed vectors as well as utilizing transfection reagents (Olson et al. 2012; Zhang et al. 2010b; Kosaka et al. 2010; Ohno et al. 2013). For instance, in a rat model of primary brain tumour, exosomes derived from MSCs engineered to over-express anti-tumour miR-146b significantly reduced glioma xenograft growth upon intra-tumour injection (Katakowski et al. 2013a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multicellular organisms rely upon diverse and complex intercellular communications networks for a myriad of physiological processes. Disruption of these processes is implicated in the onset and propagation of disease and disorder, including the mechanisms of senescence at both cellular and organismal levels. In recent years, secreted extracellular vesicles (EVs) have been identified as a particularly novel vector by which cell-to-cell communications are enacted. EVs actively and specifically traffic bioactive proteins, nucleic acids, and metabolites between cells at local and systemic levels, modulating cellular responses in a bidirectional manner under both homeostatic and pathological conditions. EVs are being implicated not only in the generic aging process, but also as vehicles of pathology in a number of age-related diseases, including cancer and neurodegenerative and disease. Thus, circulating EVs-or specific EV cargoes-are being utilised as putative biomarkers of disease. On the other hand, EVs, as targeted intercellular shuttles of multipotent bioactive payloads, have demonstrated promising therapeutic properties, which can potentially be modulated and enhanced through cellular engineering. Furthermore, there is considerable interest in employing nanomedicinal approaches to mimic the putative therapeutic properties of EVs by employing synthetic analogues for targeted drug delivery. Herein we describe what is known about the origin and nature of EVs and subsequently review their putative roles in biology and medicine (including the use of synthetic EV analogues), with a particular focus on their role in aging and age-related brain diseases.
    Biogerontology 06/2014; 16(2). DOI:10.1007/s10522-014-9510-7 · 3.29 Impact Factor
  • Source
    • "The use of MSCs in the treatment of neurodegenerative diseases, particularly in fatal and difficult to treat disorders, such as AD and PD (see previous section), is under debate. Nonetheless, current data supports that MSC transplantation is safe and may be used to slow down the progression of neurodegenerative diseases (Uccelli et al. 2011; Mezey 2007; Olson et al. 2011; Spees et al. 2006). For example, previous reports demonstrated that MSCs survive following transplantation into different mouse models, can differentiate into neural cells and promote recovery of brain function (Mezey 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aging is accompanied by reduced regenerative capacity of all tissues and organs and dysfunction of adult stem cells. Notably, these age-related alterations contribute to distinct pathophysiological characteristics depending on the tissue of origin and function and thus require special attention in a type by type manner. In this paper, we review the current understanding of the mechanisms leading to tissue-specific adult stem cell dysfunction and reduced regenerative capacity with age. A comprehensive investigation of the hematopoietic, the neural, the mesenchymal, and the skeletal stem cells in age-related research highlights that distinct mechanisms are associated with the different types of tissue stem cells. The link between age-related stem cell dysfunction and human pathologies is discussed along with the challenges and the future perspectives in stem cell-based therapies in age-related diseases.
    Biogerontology 10/2013; 14(6). DOI:10.1007/s10522-013-9469-9 · 3.29 Impact Factor
  • Source
    • "Human umbilical vein endothelial cells were obtained from human umbilical cords, expanded and maintained as previously described under an approved UC Davis IRB protocol (Olson et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Establishing vascularization is a critical obstacle to the generation of engineered heart tissue (EHT) of substantial thickness. Addition of endothelial cells to the formative stages of EHT has been demonstrated to result in prevascularization, or the formation of capillary-like structures. The detailed study of the effects of prevascularization on EHT contractile function is lacking. Here, we evaluated the functional impact of prevascularization by human umbilical vein endothelial cells (HUVECs) in self-organizing EHT. EHT fibers were generated by the self-organization of neonatal rat cardiac cells on a fibrin hydrogel scaffold with or without HUVECs. Contractile function was measured and force-length relationship and rate of force production were assessed. Immunofluorescent studies were used to evaluate arrangement and distribution of HUVECs within the EHT fibers. RT-PCR was used to assess the transcript levels of hypoxia inducible factor-1a (Hif-1α). EHT with HUVECs manifested tubule-like structures at the periphery during fiber formation. After fiber formation, HUVECs were heterogeneously located throughout the EHT fiber and human CD31+ tubule-like structures were identified. The expression level of Hif-1α did not change with the addition of HUVECs. However, maximal force and rate of force generation were not improved in HUVECs containing EHT as compared to control EHT fibers. The addition of HUVECs may result in sparse microvascularization of EHT. However, this perceived benefit is overshadowed by a significant decrease in contractile function and highlights the need for perfused vascularization strategies in order to generate EHT that approaches clinically relevant dimensions.
    Cell and Tissue Research 09/2012; 350(3). DOI:10.1007/s00441-012-1492-7 · 3.57 Impact Factor
Show more